Insmed Stock Surges 168% in the Past Six Months: Here's Why

Shares of Insmed (INSM) have more than doubled in market value in the past six months against the industry's 1.1% fall. During this timeframe, the stock has also outperformed the sector and the S&P 500. The surge in stock price can be attributed to the company's progress with its two pipeline candidates, brensocatib and treprostinil palmitil inhalation powder (TPIP), which are being developed in separate clinical studies targeting multiple lung disorders. The company's shares are also trading above the 50-d ...